Fig. 3From: Turnover of type I and III collagen predicts progression of idiopathic pulmonary fibrosisChange from baseline over time in type I and III collagen turnover in treated and untreated IPF patients. Percent change from baseline in C1M (A), PRO-C3 (B) and, C3M (C) at six months and 12 months for treated (nintedanib/pirfenidone) (Dark blue) and non-treated (grey) patients with IPF. Data are presented as mean and 95% CI (error bars) adjusted for age, sex and baseline levels of C1M, PRO-C3 or C3M. The number of evaluable samples available for analysis at each time point is provided in the graph. The P-values for the interaction between visit and treatment status for C1M (P = 0.18), PRO-C3 (P = 0.82) and for C3M (P = 0.79)Back to article page